Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)

Conditions:   Cardiovascular Diseases;   Mortality;   Type 2 Diabetes Mellitus;   Cognitive Decline;   Mental Well-being;   Kidney Function
Interventions:   Behavioral: Dietary intake;   Behavioral: Lifestyle factors;   Biological: Blood biomarkers;   Biological: Health;   Genetic: DNA;   Biological: Mental well-being
Sponsor:   Wageningen University
Active, not recruiting - verified June 2017

IRIS-BioFreedom Cohort in the IRIS-DES Registry

Condition:   Coronary Stenosis
Intervention:   Device: BioFreedom stent
Sponsors:   Duk-Woo Park;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified June 2017

Vitamin D Supplementation on Metabolic Syndrome Indicators Among Older Adults, Alborz Province, Iran

Conditions:   Vitamin D Deficiency;   Diabetes Mellitus;   Hypertension;   Lipid Metabolism Disorders;   Obesity, Abdominal
Interventions:   Drug: D-vitin, soft gelatin capsule (vitamin D3,50000 IU);   Drug: Placebo vitamin D3
Sponsors:   Alborz Medical University;   Universiti Putra Malaysia
Enrolling by invitation - verified June 2017

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

Condition:   Venous Thromboembolism
Interventions:   Drug: Warfarin;   Drug: Apixaban 2.5 MG;   Drug: Rivaroxaban 20 MG
Sponsors:   Duke University;   Patient-Centered Outcomes Research Institute
Not yet recruiting - verified June 2017

Detection of Atrial Fibrillation in the Hospital Setting by Use of a Handheld ECG Recording Device

Condition:   Atrial Fibrillation
Intervention:   Device: Zenicor ECG
Sponsor:   Stéphane Cook, Prof
Not yet recruiting - verified June 2017

Effects of the Insole on Balance Capacity in Chronic Stroke

Condition:   Stroke, Cardiovascular
Intervention:   Other: insole
Sponsor:   Taipei Medical University WanFang Hospital
Not yet recruiting - verified May 2017

Behavior of Valve Leaflets

Condition:   Aortic-valve Replacement
Interventions:   Diagnostic Test: 4D Cardiac CT Scan;   Device: LivaNova Bioprothetic Aortic Valve Implant
Sponsor:   LivaNova
Not yet recruiting - verified June 2017

Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome

Conditions:   Acute Coronary Syndrome;   Percutaneous Coronary Intervention;   Drug-Eluting Stents
Interventions:   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsor:   Thorax Centrum Twente
Completed - verified June 2017

Optical Coherence Tomography in Acute Coronary Syndrome

Conditions:   Acute Coronary Syndrome;   STEMI - ST Elevation Myocardial Infarction;   NSTEMI - Non-ST Segment Elevation MI;   Atherosclerosis, Coronary
Intervention:  
Sponsors:   Charite University, Berlin, Germany;   Berlin Institut of Health (BIH), Germany
Recruiting - verified June 2017

VItamin D as a Novel Determinant of Injurious Cardiac Remodelling After acuTE Myocardial Infarction

Conditions:   Myocardial Infarction;   Heart Failure, Systolic
Intervention:  
Sponsor:   University of Leeds
Not yet recruiting - verified June 2017

Safety and Efficacy Comparison Of Two TAVI Systems in a Prospective Randomized Evaluation II

Condition:   Aortic Valve Stenosis
Interventions:   Device: Symetis ACURATE neo™ transfemoral TAVI system;   Device: Medtronic CoreValve Evolut R TAVI System
Sponsors:   Ceric Sàrl;   Symetis SA
Recruiting - verified June 2017

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Conditions:   Type2 Diabetes;   Dyslipidemia
Interventions:   Drug: K-877;   Drug: Placebo
Sponsors:   Kowa Research Institute, Inc.;   Brigham and Women's Hospital
Recruiting - verified June 2017

Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF)

Condition:   Idiopathic Pulmonary Fibrosis
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified June 2017

Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction

Condition:   STEMI
Intervention:   Device: Impella unloading prior to PPCI
Sponsor:   Abiomed Inc.
Recruiting - verified December 2016

the Effect of Prolonged Inflation Time During Stents Deployment for ST-elevation Myocardial Infarction

Condition:   Acute ST-elevation Myocardial Infarction
Interventions:   Device: deploying the Drug-eluting Stents with a prolonged time;   Device: deploying the Drug-eluting Stents with a conventional time
Sponsor:   West China Hospital
Recruiting - verified June 2017

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction

Condition:   Myocardial Infarction
Interventions:   Drug: BAY1142524;   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified June 2017

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS

Condition:   ST Elevation Myocardial Infarction
Interventions:   Drug: DLBS1033;   Drug: Placebo;   Drug: Standard therapy
Sponsors:   Dexa Medica Group;   Binawaluya Cardiac Hospital, Jakarta
Recruiting - verified June 2017

Quantitative Coronary Angiography Versus Intravascular Ultrasound GUIDancE for Drug-Eluting Stent Implantation

Conditions:   Coronary Disease;   Coronary Stenoses
Interventions:   Device: quantitative coronary angiography guided coronary intervention with drug-eluting stent;   Device: intravascular ultrasound guided coronary intervention with drug-eluting stent
Sponsors:   CHEOL WHAN LEE, M.D., Ph.D;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2017

Post Infarction Exercise Effects on Myocardial Function Assessed by 2D Strain Ultrasound

Condition:   Myocardial Infarction
Intervention:   Other: Cardiac training program
Sponsor:   Centre Hospitalier Universitaire de Nīmes
Recruiting - verified October 2016

Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events

Conditions:   Percutaneous Transluminal Coronary Angioplasty;   Coronary Disease
Interventions:   Drug: aspirin and clopidogrel;   Drug: Clopidogrel only
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2017

Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Condition:   Node Positive HER2 Negative Breast Cancer
Interventions:   Other: Placebo;   Drug: Aspirin
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer
Recruiting - verified June 2017

Psilocybin for the Treatment of Cluster Headache

Condition:   Cluster Headache
Interventions:   Drug: 0.143 mg/kg Psilocybin;   Drug: 0.0143 mg/kg Psilocybin;   Drug: Placebo
Sponsors:   Yale University;   Heffter Research Institute
Recruiting - verified June 2017

High Intensity Aerobic Interval Training With Mediterranean Diet Recommendations in Post-Myocardial Infarct Patients

Condition:   Myocardial Infarction
Interventions:   Other: HIGH VOLUME (HV) Supervised exercise;   Other: Mediterranean Diet Recommendations;   Other: Physical Activity Recommendations;   Other: LOW VOLUME (LW) Supervised exercise
Sponsors:   Basque Country University;   HOSPITAL SANTIAGO APOSTOL. MIRANDA DE EBRO. BURGOS. SPAIN
Recruiting - verified June 2017

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: rhEPO;   Drug: Placebo;   Drug: Iron therapy
Sponsor:   GlaxoSmithKline
Recruiting - verified June 2017

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
Sponsor:   GlaxoSmithKline
Recruiting - verified June 2017

LEADERS FREE II: BioFreedom™ Pivotal Study

Conditions:   Acute Coronary Syndrome;   High Bleeding Risk
Interventions:   Device: BioFreedom™ Drug Coated Coronary Stent System;   Drug: Dual Antiplatelet Therapy
Sponsor:   Biosensors Europe SA
Recruiting - verified June 2017

Intravascular Ultrasound Prediction of Myocardial Size and Coronary Computed Tomography-Derived Ischemic Burden for Coronary Lesion

Condition:   Coronary Artery Disease
Intervention:   Other: Intravascular Ultrasound, coronary computed tomography angiography
Sponsors:   Asan Medical Center;   Boston Scientific Corporation
Recruiting - verified June 2017

Interest of CARE Rule to Exclude the Hypothesis of an Acute Coronary Syndrome Without Bioassay - ICARE

Condition:   Chest Pain
Intervention:   Other: CARE Rule
Sponsor:   University Hospital, Angers
Recruiting - verified June 2017

Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery

Condition:   Antiplatelet Drugs
Interventions:   Drug: Aspirin only;   Drug: No antiplatelet therapy
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2017

Statin Therapy In Patients With Vasospastic Angina

Conditions:   Angina Pectoris, Variant;   Statins, HMG-CoA
Interventions:   Drug: Atorvastatin;   Drug: Placebo
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Withdrawn - verified June 2017

Sex and Gender Differences in Ischemic Heart Disease - Endocrine Vascular Disease Approach

Condition:   Myocardial Ischemia
Intervention:   Procedure: percutaneous coronary intervention
Sponsors:   University of Roma La Sapienza;   Ministry of Education, Universities and Research, Italy
Recruiting - verified June 2017

IRIS-BVS AMI Registry

Conditions:   Arterial Occlusive Diseases;   Cardiovascular Diseases;   Coronary Artery Disease
Intervention:   Device: Bioresorbable Vascular Scaffold
Sponsors:   Duk-Woo Park, MD;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2017

IRIS Ultimaster Cohort in the IRIS-DES Registry

Condition:   Coronary Artery Disease
Intervention:   Device: Ultimaster stent
Sponsors:   Duk-Woo Park, MD;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2017

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2017

Acute Kidney Injury Genomics and Biomarkers in TAVR Study

Conditions:   Acute Kidney Injury;   Renal Insufficiency, Chronic;   Heart Failure;   Myocardial Infarction;   Arrhythmias, Cardiac;   Stroke
Intervention:   Procedure: Transcatheter Aortic Valve Replacement
Sponsor:   University of Texas Southwestern Medical Center
Recruiting - verified June 2017

Randomized Comparison of DCB for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease

Conditions:   Angioplasty, Balloon;   Catheterization, Peripheral;   Popliteal Artery;   Femoral Artery
Interventions:   Device: IN.PACT drug coated balloon;   Device: Lutonix drug coated balloon
Sponsor:   Seung-Whan Lee, M.D., Ph.D.
Recruiting - verified June 2017

Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice

Conditions:   Arterial Occlusive Diseases;   Cardiovascular Diseases;   Coronary Artery Disease;   Coronary Disease
Intervention:   Device: Bioresorbable Vascular Scaffold
Sponsors:   Duk-Woo Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2017

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

Conditions:   Arterial Occlusive Diseases;   Coronary Artery Disease;   Coronary Disease;   Arteriosclerosis;   Heart Diseases;   Myocardial Ischemia;   Vascular Diseases;   Acute Coronary Syndrome
Interventions:   Drug: PZ-128;   Drug: Placebo
Sponsors:   Tufts Medical Center;   National Heart, Lung, and Blood Institute (NHLBI);   RTI International;   Inova Fairfax Hospital;   University of Massachusetts, Worcester
Recruiting - verified June 2017

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Condition:   Transcatheter Aortic Valve Replacement
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Acetylsalicylic acid;   Drug: Clopidogrel
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified June 2017

Feasibility Study of a Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Device: Aegis Sierra Ligation System
Sponsors:   Aegis Medical Innovations;   Applied Health Research Centre
Recruiting - verified June 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified June 2017

XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS)

Conditions:   Ischemic Heart Disease;   Angina Pectoris;   Coronary Artery Disease;   Myocardial Ischemia
Intervention:   Device: XIENCE Xpedition 2.25 mm stent
Sponsor:   Abbott Vascular
Active, not recruiting - verified June 2017

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Active, not recruiting - verified June 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified June 2017

LAA Excision With AF Ablation Versus Oral Anticoagulants for Secondary Prevention of Stroke

Conditions:   Atrial Fibrillation;   Stroke;   Systemic Embolism
Interventions:   Procedure: Thoracoscopic LAA Excision plus AF Ablation;   Drug: Warfarin or Novel Oral Anticoagulants
Sponsor:   The First Affiliated Hospital with Nanjing Medical University
Recruiting - verified June 2017

The Bicuspid Aortic Stenosis Following Transcatheter Aortic Valve Replacement Registry

Conditions:   Aortic Valve Stenosis;   Cardiovascular Diseases;   Heart Valve Diseases;   Bicuspid
Intervention:   Procedure: transcatheter aortic valve replacement
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2017

Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM

Condition:   Ischemic Stroke
Interventions:   Drug: Naoxintong Capsule;   Drug: Placebo
Sponsors:   Xiaofei Yu;   Shanghai Municipal Science and Technology Commission
Recruiting - verified June 2017

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified June 2017

Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)

Condition:   Tricuspid Regurgitation
Intervention:   Device: Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava
Sponsor:   Temple University
Recruiting - verified June 2017

The Preventive Implantation of Bioresorbable Vascular Scaffold on Functionally Insignificant Stenosis With Vulnerable Plaque Characteristics

Conditions:   Coronary Artery Disease;   Plaque, Atherosclerotic
Interventions:   Device: Bioresorbable Vascular Scaffold;   Drug: Optimal Medical treatment
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2017

The Asian Transcatheter Aortic Valve Replacement Registry

Conditions:   Aortic Valve Stenosis;   Aortic Diseases
Intervention:   Device: transcatheter aortic valve replacement
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2017

Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Conditions:   Recurrent Melanoma of the Skin;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Questionnaire Administration;   Biological: Sargramostim
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2017

PARACHUTE III Pressure Volume Loop Sub-Study

Conditions:   Heart Failure;   Myocardial Infarction
Intervention:  
Sponsor:   CardioKinetix, Inc
Terminated - verified June 2017

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified June 2017

Prospective Evaluation of MyocaRdial PerFUSion ComputEd Tomography Trial

Condition:   Coronary Disease
Interventions:   Device: computed tomography perfusion guided treatment;   Device: Fractional flow reserve guided treatment
Sponsor:   Young-Hak Kim, MD, PhD
Recruiting - verified June 2017

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified June 2017

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

Conditions:   Lung Cancer;   Breast Cancer;   Prostate Cancer;   Tumors (Others);   Ovarian Cancer
Intervention:   Biological: MVA-brachyury- TRICOM
Sponsor:   National Cancer Institute (NCI)
Completed - verified April 6, 2017

Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management

Conditions:   Acute Coronary Syndrome;   Myocardial Ischemia;   Heart Diseases;   Cardiovascular Diseases;   Angina Pectoris
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Active, not recruiting - verified June 2017

Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES

Condition:   Coronary Artery Disease
Interventions:   Drug: P2Y12 antagonist monotherapy;   Drug: aspirin plus P2Y12 antagonist
Sponsor:   Samsung Medical Center
Recruiting - verified June 2017

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

Condition:   HIV Infection
Interventions:   Drug: Aspirin 81 mg daily;   Drug: Atorvastatin 40 mg daily
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified July 29, 2016

XIENCE Xpedition/Alpine in Routine Clinical Practice

Conditions:   Percutaneous Transluminal Coronary Angioplasty;   Coronary Artery Disease
Intervention:   Device: XIENCE Xpedition/Alpine
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Abbott
Recruiting - verified June 2017

Drug-Eluting Balloon Registry in Routine Clinical Practice

Conditions:   Coronary Artery Disease;   Angioplasty, Balloon
Intervention:   Device: Balloon angioplasty
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   B. Braun Korea Co., Ltd.
Recruiting - verified June 2017

Asan Multivessel Registry

Condition:   Coronary Artery Disease
Intervention:   Other: Treatment
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2017

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Completed - verified June 2017

To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels

Conditions:   Coronary Disease;   Coronary Artery Disease;   Coronary Restenosis
Intervention:   Device: Absorb BVS
Sponsor:   Abbott Vascular
Active, not recruiting - verified February 2017

Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus-eluting Stent

Condition:   Coronary Artery Disease
Interventions:   Device: Abbott Laboratories Xience;   Device: Biotronik Orsiro
Sponsor:   Biotronik AG
Active, not recruiting - verified June 2017

Antibody Treatment for Advanced Celiac Disease

Conditions:   Celiac Disease;   Celiac Sprue;   Gluten Enteropathy;   Gluten-Sensitive Enteropathy
Intervention:   Biological: Hu-Mik- Beta-1
Sponsors:   National Cancer Institute (NCI);   Mayo Clinic
Recruiting - verified March 2, 2017

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Completed - verified June 2017

Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib

Condition:   Leukemia
Intervention:   Drug: Ponatinib
Sponsors:   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
Active, not recruiting - verified June 2017

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   High Risk for Cardiovascular Event
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Placebo tablet
Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   The TIMI Study Group;   Hadassah Medical Organization
Active, not recruiting - verified June 2017

Anti-inflammatory Effects of Colchicine in PCI

Condition:   Coronary Artery Disease
Interventions:   Drug: Colchicine;   Drug: Placebo
Sponsors:   New York University School of Medicine;   Takeda
Recruiting - verified June 2017

STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial

Conditions:   Intracerebral Haemorrhage;   Stroke
Interventions:   Drug: Tranexamic Acid;   Drug: Placebo
Sponsor:   Neuroscience Trials Australia
Recruiting - verified June 2017

Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

Conditions:   Aplastic Anemia;   Neutropenia;   Pancytopenia;   Anemia;   Thrombocytopenia
Interventions:   Drug: Eltrombopag;   Drug: Horse Anti-Thymocyte Globulin (ATG);   Drug: Cyclosporine A (CSA)
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 6, 2017

A Multinational Trial to Evaluate the Longterm Safety of the Parachute Implant System

Conditions:   Heart Failure;   Myocardial Infarction
Intervention:  
Sponsor:   CardioKinetix, Inc
Terminated - verified June 2017

A Multinational Trial To Evaluate The Parachute Implant System

Conditions:   Heart Failure;   Myocardial Infarction
Intervention:   Device: Parachute Implant
Sponsor:   CardioKinetix, Inc
Terminated - verified June 2017

Karolinska Cardiorenal Theme-centre and StockholmHeartbank

Conditions:   Chronic Kidney Disease;   Chronic Renal Failure;   Acute Coronary Syndrome;   Ischemic Heart Disease;   Myocardial Infarction
Intervention:  
Sponsors:   Danderyd Hospital;   Stockholm County Council, Sweden;   Karolinska Institutet;   Uppsala University;   Lund University;   Stockholm South General Hospital;   Karolinska University Hospital
Recruiting - verified June 2017

Carvedilol Post-intervention Long-term Administration in Large-scale Trial

Condition:   Myocardial Infarction
Interventions:   Drug: Carvedilol;   Drug: No Carvedilol
Sponsor:   Takeshi Morimoto
Completed - verified June 2017

Stent Thrombosis In Acute Coronary Syndromes

Conditions:   Stent Thrombosis;   Acute Coronary Syndrome
Intervention:  
Sponsors:   University of California, Davis;   University of California, San Diego
Recruiting - verified June 2017

Associations Between Diabetes Care and Haptoglobin Genotype On outComes

Conditions:   Diabetes;   Cardiovascular Disease;   Myocardial Infarction;   Stroke
Intervention:  
Sponsor:   Clalit Health Services
Active, not recruiting - verified June 2017

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Condition:   Chronic Renal Anemia
Interventions:   Drug: Darbepoetin Alfa;   Drug: Epoetin Alfa;   Drug: Epoetin Beta;   Drug: methoxy polyethylene glycol-epoetin beta
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified June 2017

Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

Conditions:   Coronary Artery Disease;   Carotid Artery Diseases;   Atherosclerosis
Interventions:   Drug: Atorvastatin;   Drug: Niacin;   Drug: Colesevelam;   Drug: Placebo Niacin;   Drug: Placebo Colesevelam
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI);   Pfizer;   Abbott;   Daiichi Sankyo Inc.;   Upsher-Smith Laboratories
Active, not recruiting - verified June 2017

GORE® HELEX® Septal Occluder / GORE® Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients - The Gore REDUCE Clinical Study

Conditions:   Stroke;   Transient Ischemic Attack
Interventions:   Device: GORE® HELEX® Septal Occluder / GORE® Septal Occluder;   Other: Antiplatelet Medical Therapy
Sponsor:   W.L.Gore & Associates
Active, not recruiting - verified June 2017

Technical Development of Cardiovascular Magnetic Resonance Imaging

Condition:   Cardiovascular Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 14, 2017